P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.

por Vesole, David H., Berdeja, Jesus, Matous, Jeffrey, Trudel, Suzanne, Schade, Henning, Munster, Pamela, Berkeley, Savannah, Sun, Benjamin, Martin, Tom
Publicado 2023

Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients

por Kotchetkov, Rouslan, Masih‐Khan, Esther, Chu, Chia‐Min, Atenafu, Eshetu G., Chen, Christine, Kukreti, Vishal, Trudel, Suzanne, Tiedemann, Rodger, Reece, Donna E.
Publicado 2016

Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression

por Croucher, Danielle C., Devasia, Anup Joseph, Abelman, Dor D., Mahdipour-Shirayeh, Ali, Li, Zhihua, Erdmann, Natalie, Tiedemann, Rodger, Pugh, Trevor J., Trudel, Suzanne
Publicado 2023

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

por Mateos, Maria-Victoria, Bahlis, Nizar J, Spencer, Andrew, Kaedbey, Rayan, Rodríguez-Otero, Paula, Harrison, Simon, Wong, Chihunt, Goodman, Grant, Nakamura, Rin, Choeurng, Voleak, Cooper, James, Trudel, Suzanne
Publicado 2023

A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)

por Liyasova, Mariya, McDonald, Zac, Taylor, Paul, Gorospe, Kathleen, Xu, Xin, Yao, Chenyu, Liu, Qixin, Yang, Liqiang, Atenafu, Eshetu G., Piza, Giovanni, Ma, Bin, Reece, Donna, Trudel, Suzanne
Publicado 2021

Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing

por Chow, Signy, Kis, Olena, Mulder, David T, Danesh, Arnavaz, Bruce, Jeff, Wang, Ting Ting, Reece, Donna, Bhalis, Nizar, Neri, Paola, Sabatini, Peter JB, Keats, Jonathan, Trudel, Suzanne, Pugh, Trevor J
Publicado 2022

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

por Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Hoos, Axel, Gupta, Ira, Bragulat, Veronique, He, Zangdong, Opalinska, Joanna B., Cohen, Adam D.
Publicado 2019

MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up

por Cohen, Adam D, Lee, Hans C, Trudel, Suzanne, Abdallah, Al-Ola, Callander, Natalie, Libby, Edward, Karlin, Lionel, Lonial, Sagar, Womersley, Lynsey, Baron, January, Lewis, Eric, Nungesser, Katlyn, Gupta, Ira, Opalinska, Joanna
Publicado 2020

Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression

por Croucher, Danielle C., Richards, Laura M., Tsofack, Serges P., Waller, Daniel, Li, Zhihua, Wei, Ellen Nong, Huang, Xian Fang, Chesi, Marta, Bergsagel, P. Leif, Sebag, Michael, Pugh, Trevor J., Trudel, Suzanne
Publicado 2021

The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma

por Longo, Joseph, Smirnov, Petr, Li, Zhihua, Branchard, Emily, van Leeuwen, Jenna E., Licht, Jonathan D., Haibe-Kains, Benjamin, Andrews, David W., Keats, Jonathan J., Pugh, Trevor J., Trudel, Suzanne, Penn, Linda Z.
Publicado 2020

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates

por Kis, Olena, Kaedbey, Rayan, Chow, Signy, Danesh, Arnavaz, Dowar, Mark, Li, Tiantian, Li, Zhihua, Liu, Jessica, Mansour, Mark, Masih-Khan, Esther, Zhang, Tong, Bratman, Scott V., Oza, Amit M., Kamel-Reid, Suzanne, Trudel, Suzanne, Pugh, Trevor J.
Publicado 2017

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 T...

por Bahlis, Nizar J, Trudel, Suzanne, Quach, Hang, Popat, Rakesh, Lonial, Sagar, Orlowski, Robert Z, Kim, Kihyun, Mateos, Maria-Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martinez-Lopez, Joaquín, Casas-Avilés, Ignacio, Spirli, Alessia, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Richardson, Paul
Publicado 2023

Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

por Reeder, Craig B., Reece, Donna E., Kukreti, Vishal, Chen, Christine, Trudel, Suzanne, Hentz, Joseph, Noble, Brie, Pirooz, Nicholas A., Spong, Jacy E., Piza, Jesus G., Zepeda, Victor H. Jimenez, Mikhael, Joseph R., Leis, Jose F., Bergsagel, P. Leif, Fonseca, Rafael, Stewart, A. Keith
Publicado 2009

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

por Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.
Publicado 2021

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

por Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.
Publicado 2023

Initial genome sequencing and analysis of multiple myeloma

por Chapman, Michael A., Lawrence, Michael S., Keats, Jonathan J., Cibulskis, Kristian, Sougnez, Carrie, Schinzel, Anna C., Harview, Christina L., Brunet, Jean-Philippe, Ahmann, Gregory J., Adli, Mazhar, Anderson, Kenneth C., Ardlie, Kristin G., Auclair, Daniel, Baker, Angela, Bergsagel, P. Leif, Bernstein, Bradley E., Drier, Yotam, Fonseca, Rafael, Gabriel, Stacey B., Hofmeister, Craig C., Jagannath, Sundar, Jakubowiak, Andrzej J., Krishnan, Amrita, Levy, Joan, Liefeld, Ted, Lonial, Sagar, Mahan, Scott, Mfuko, Bunmi, Monti, Stefano, Perkins, Louise M., Onofrio, Robb, Pugh, Trevor J., Vincent Rajkumar, S., Ramos, Alex H., Siegel, David S., Sivachenko, Andrey, Trudel, Suzanne, Vij, Ravi, Voet, Douglas, Winckler, Wendy, Zimmerman, Todd, Carpten, John, Trent, Jeff, Hahn, William C., Garraway, Levi A., Meyerson, Matthew, Lander, Eric S., Getz, Gad, Golub, Todd R.
Publicado 2011

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

por Anderson, Kenneth C., Auclair, Daniel, Adam, Stacey J., Agarwal, Amit, Anderson, Melissa, Avet-Loiseau, Hervé, Bustoros, Mark, Chapman, Jessica, Connors, Dana E., Dash, Ajeeta, Di Bacco, Alessandra, Du, Ling, Facon, Thierry, Flores-Montero, Juan, Gay, Francesca, Ghobrial, Irene M., Gormley, Nicole J., Gupta, Ira, Higley, Howard, Hillengass, Jens, Kanapuru, Bindu, Kazandjian, Dickran, Kelloff, Gary J., Kirsch, Ilan R., Kremer, Brandon, Landgren, Ola, Lightbody, Elizabeth, Lomas, Oliver C., Lonial, Sagar, Mateos, María-Victoria, Montes de Oca, Rocio, Mukundan, Lata, Munshi, Nikhil C., O'Donnell, Elizabeth K., Orfao, Alberto, Paiva, Bruno, Patel, Reshma, Pugh, Trevor J., Ramasamy, Karthik, Ray, Jill, Roshal, Mikhail, Ross, Jeremy A., Sigman, Caroline C., Thoren, Katie L., Trudel, Suzanne, Ulaner, Gary, Valente, Nancy, Weiss, Brendan M., Zamagni, Elena, Kumar, Shaji K.
Publicado 2021